The ubiquitin proteasome system in Huntington's disease and the spinocerebellar ataxias

BMC Biochemistry

Volumn 8, Issue SUPPL. 1, 2007, Pages

  Davies, Janet E ^a   Sarkar, Sovan ^a   Rubinsztein, David C ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPOXOMICIN; LACTACYSTIN; POLYGLUTAMINE; PROTEASOME; RAPAMYCIN; UBIQUITIN; UBIQUITIN PROTEIN LIGASE;

DRUG MECHANISM; ENZYME SUBSTRATE; HUMAN; HUNTINGTON CHOREA; NEUROPROTECTION; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVIEW; SPINOCEREBELLAR DEGENERATION; ANIMAL; ENZYMOLOGY; GENETICS; METABOLISM;

ANIMALS; HUMANS; HUNTINGTON DISEASE; PROTEASOME ENDOPEPTIDASE COMPLEX; SPINOCEREBELLAR ATAXIAS; UBIQUITIN; UBIQUITIN-PROTEIN LIGASE COMPLEXES;

EID: 38449083555     PISSN: None     EISSN: 14712091     Source Type: Journal    
DOI: 10.1186/1471-2091-8-S1-S2     Document Type: Review

References (64)

1. Molecular genetics: unmasking polyglutamine triggers in neurodegenerative disease. JF Gusella ME MacDonald, Nat Rev Neurosci 2000 1 2 109 115 10.1038/35039051 11252773
2. How does the Huntington's disease mutation damage cells? DC Rubinsztein, Sci Aging Knowledge Environ 2003 2003 37 PE26 10.1126/sageke.2003.37.pe26 13679594
3. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. M DiFiglia E Sapp KO Chase SW Davies GP Bates JP Vonsattel N Aronin, Science 1997 277 5334 1990 1993 10.1126/science.277.5334. 1990 9302293
4. Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. HL Paulson MK Perez Y Trottier JQ Trojanowski SH Subramony SS Das P Vig JL Mandel KH Fischbeck RN Pittman, Neuron 1997 19 2 333 344 10.1016/S0896-6273(00)80943-5 9292723
5. Toxic proteins in neurodegenerative disease. JP Taylor J Hardy KH Fischbeck, Science 2002 296 5575 1991 1995 10.1126/science.1067122 12065827
6. Bidirectional expression of CUG and CAG expansion transcripts and intranuclear polyglutamine inclusions in spinocerebellar ataxia type 8. ML Moseley T Zu Y Ikeda W Gao AK Mosemiller RS Daughters G Chen MR Weatherspoon HB Clark TJ Ebner, Nat Genet 2006 38 7 758 769 10.1038/ng1827 16804541
7. Transcriptional abnormalities in Huntington disease. KL Sugars DC Rubinsztein, Trends Genet 2003 19 5 233 238 10.1016/S0168-9525(03)00074-X 12711212
8. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. C Zuccato A Ciammola D Rigamonti BR Leavitt D Goffredo L Conti ME MacDonald RM Friedlander V Silani MR Hayden, Science 2001 293 5529 493 498 10.1126/science.1059581 11408619
9. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. C Zuccato M Tartari A Crotti D Goffredo M Valenza L Conti T Cataudella BR Leavitt MR Hayden T Timmusk, Nat Genet 2003 35 1 76 83 10.1038/ng1219 12881722
10. Mitochondria take center stage in aging and neurodegeneration. MF Beal, Ann Neurol 2005 58 4 495 505 10.1002/ana.20624 16178023
11. Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in Drosophila. S Gunawardena LS Her RG Brusch RA Laymon IR Niesman B Gordesky-Gold L Sintasath NM Bonini LS Goldstein, Neuron 2003 40 1 25 40 10.1016/S0896-6273(03)00594-4 14527431
12. HIP14, a novel ankyrin domain-containing protein, links huntingtin to intracellular trafficking and endocytosis. RR Singaraja S Hadano M Metzler S Givan CL Wellington S Warby A Yanai CA Gutekunst BR Leavitt H Yi, Hum Mol Genet 2002 11 23 2815 2828 10.1093/hmg/11.23.2815 12393793
13. Impairment of the ubiquitin-proteasome system by protein aggregation. NF Bence RM Sampat RR Kopito, Science 2001 292 5521 1552 1555 10.1126/science.292. 5521.1552 11375494
14. Global impairment of the ubiquitin-proteasome system by nuclear or cytoplasmic protein aggregates precedes inclusion body formation. EJ Bennett NF Bence R Jayakumar RR Kopito, Mol Cell 2005 17 3 351 365 10.1016/j.molcel.2004. 12.021 15694337
15. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. NR Jana EA Zemskov G Wang N Nukina, Hum Mol Genet 2001 10 10 1049 1059 10.1093/hmg/10.10. 1049 11331615
16. Molecular pathogenesis of spinocerebellar ataxias. AM Duenas R Goold P Giunti, Brain 2006 129 Pt 6 1357 1370 10.1093/brain/awl081 16613893
17. Intracellular protein degradation: from a vague idea thru the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting. A Ciechanover, Exp Biol Med (Maywood) 2006 231 7 1197 1211 16816126
18. Protein degradation and protection against misfolded or damaged proteins. AL Goldberg, Nature 2003 426 6968 895 899 10.1038/nature02263 14685250
19. Activity-dependent dynamics and sequestration of proteasomes in dendritic spines. B Bingol EM Schuman, Nature 2006 441 7097 1144 1148 10.1038/nature04769 16810255
20. Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1. CJ Cummings MA Mancini B Antalffy DB DeFranco HT Orr HY Zoghbi, Nat Genet 1998 19 2 148 154 10.1038/502 9620770
21. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. SW Davies M Turmaine BA Cozens M DiFiglia AH Sharp CA Ross E Scherzinger EE Wanker L Mangiarini GP Bates, Cell 1997 90 3 537 548 10.1016/S0092-8674(00)80513-9 9267033
22. Polyglutamine protein aggregates are dynamic. S Kim EA Nollen K Kitagawa VP Bindokas RI Morimoto, Nat Cell Biol 2002 4 10 826 831 10.1038/ncb863 12360295
23. Inefficient degradation of truncated polyglutamine proteins by the proteasome. CI Holmberg KE Staniszewski KN Mensah A Matouschek RI Morimoto, Embo J 2004 23 21 4307 4318 15470501 10.1038/sj.emboj.7600426
24. Eukaryotic proteasomes cannot digest polyglutamine sequences and release them during degradation of polyglutamine-containing proteins. P Venkatraman R Wetzel M Tanaka N Nukina AL Goldberg, Mol Cell 2004 14 1 95 104 10.1016/S1097-2765(04)00151-0 15068806
25. Inhibition of 26S proteasome activity by huntingtin filaments but not inclusion bodies isolated from mouse and human brain. M Diaz-Hernandez AG Valera MA Moran P Gomez-Ramos B Alvarez-Castelao JG Castano F Hernandez JJ Lucas, J Neurochem 2006 16787406
26. Association of ataxin-7 with the proteasome subunit S4 of the 19S regulatory complex. A Matilla C Gorbea DD Einum J Townsend A Michalik C van Broeckhoven CC Jensen KJ Murphy LJ Ptacek YH Fu, Hum Mol Genet 2001 10 24 2821 2831 10.1093/hmg/10.24.2821 11734547
27. Identification and characterization of an ataxin-1-interacting protein: A1Up, a ubiquitin-like nuclear protein. JD Davidson B Riley EN Burright LA Duvick HY Zoghbi HT Orr, Hum Mol Genet 2000 9 15 2305 2312 11001934
28. The solution structure of the Josephin domain of ataxin-3: structural determinants for molecular recognition. G Nicastro RP Menon L Masino PP Knowles NQ McDonald A Pastore, Proc Natl Acad Sci U S A 2005 102 30 10493 10498 16020535 10.1073/pnas.0501732102
29. Proteasome function is inhibited by polyglutamine-expanded ataxin-1, the SCA1 gene product. Y Park S Hong SJ Kim S Kang, Mol Cells 2005 19 1 23 30 15750336
30. Generalized brain and skin proteasome inhibition in Huntington's disease. H Seo KC Sonntag O Isacson, Ann Neurol 2004 56 3 319 328 10.1002/ana.20207 15349858
31. Neuronal dysfunction in a polyglutamine disease model occurs in the absence of ubiquitin-proteasome system impairment and inversely correlates with the degree of nuclear inclusion formation. AB Bowman SY Yoo NP Dantuma HY Zoghbi, Hum Mol Genet 2005 14 5 679 691 10.1093/hmg/ddi064 15661755
32. Polyglutamine expansion, protein aggregation, proteasome activity, and neural survival. Q Ding JJ Lewis KM Strum E Dimayuga AJ Bruce-Keller JC Dunn JN Keller, J Biol Chem 2002 277 16 13935 13942 10.1074/jbc.M107706200 11782460
33. Neuronal induction of the immunoproteasome in Huntington's disease. M Diaz-Hernandez F Hernandez E Martin-Aparicio P Gomez-Ramos MA Moran JG Castano I Ferrer J Avila JJ Lucas, J Neurosci 2003 23 37 11653 11661 14684867
34. Proteasome impairment does not contribute to pathogenesis in R6/2 Huntington's disease mice: exclusion of proteasome activator REGgamma as a therapeutic target. JS Bett GM Goellner B Woodman G Pratt M Rechsteiner GP Bates, Hum Mol Genet 2006 15 1 33 44 10.1093/hmg/ddi423 16311253
35. The ubiquitin-proteasome system in Huntington's disease. AG Valera M Diaz-Hernandez F Hernandez Z Ortega JJ Lucas, Neuroscientist 2005 11 6 583 594 10.1177/1073858405280639 16282599
36. Monitoring the ubiquitin/proteasome system in conformational diseases. K Lindsten NP Dantuma, Ageing Res Rev 2003 2 4 433 449 Good review of methods to study UPS activity 10.1016/S1568-1637(03)00031-X 14522245
37. Expanded polyglutamines impair synaptic transmission and ubiquitin-proteasome system in Caenorhabditis elegans. LA Khan PO Bauer H Miyazaki KS Lindenberg BG Landwehrmeyer N Nukina, J Neurochem 2006 98 2 576 587 10.1111/j.1471-4159.2006.03895.x 16805848
38. A transgenic mouse model of the ubiquitin/proteasome system. K Lindsten V Menendez-Benito MG Masucci NP Dantuma, Nat Biotechnol 2003 21 8 897 902 10.1038/nbt851 12872133
39. Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein aggregation in cellular models of Huntington's disease. A Wyttenbach J Carmichael J Swartz RA Furlong Y Narain J Rankin DC Rubinsztein, Proc Natl Acad Sci U S A 2000 97 6 2898 2903 10717003 10.1073/pnas.97.6.2898
40. Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity. JF Staropoli C McDermott C Martinat B Schulman E Demireva A Abeliovich, Neuron 2003 37 5 735 749 10.1016/S0896-6273(03)00084-9 12628165
41. Parkin facilitates the elimination of expanded polyglutamine proteins and leads to preservation of proteasome function. YC Tsai PS Fishman NV Thakor GA Oyler, J Biol Chem 2003 278 24 22044 22055 10.1074/jbc.M212235200 12676955
42. The proteasome of Mycobacterium tuberculosis is required for resistance to nitric oxide. KH Darwin S Ehrt JC Gutierrez-Ramos N Weich CF Nathan, Science 2003 302 5652 1963 1966 10.1126/science.1091176 14671303
43. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. B Ravikumar C Vacher Z Berger JE Davies S Luo LG Oroz F Scaravilli DF Easton R Duden CJ O'Kane, Nat Genet 2004 36 6 585 595 10.1038/ng1362 15146184
44. Rapamycin alleviates toxicity of different aggregate-prone proteins. Z Berger B Ravikumar FM Menzies LG Oroz BR Underwood MN Pangalos I Schmitt U Wullner BO Evert CJ O'Kane, Hum Mol Genet 2006 15 3 433 442 10.1093/hmg/ddi458 16368705
45. Rapamycin pre-treatment protects against apoptosis. B Ravikumar Z Berger C Vacher CJ O'Kane DC Rubinsztein, Hum Mol Genet 2006 15 7 1209 1216 10.1093/hmg/ddl036 16497721
46. Huntingtin is ubiquitinated and interacts with a specific ubiquitin-conjugating enzyme. MA Kalchman RK Graham G Xia HB Koide JG Hodgson KC Graham YP Goldberg RD Gietz CM Pickart MR Hayden, J Biol Chem 1996 271 32 19385 19394 10.1074/jbc.271.32.19385 8702625
47. Proteasomal-dependent aggregate reversal and absence of cell death in a conditional mouse model of Huntington's disease. E Martin-Aparicio A Yamamoto F Hernandez R Hen J Avila JJ Lucas, J Neurosci 2001 21 22 8772 8781 11698589
48. Lactacystin, a novel microbial metabolite, induces neuritogenesis of neuroblastoma cells. S Omura T Fujimoto K Otoguro K Matsuzaki R Moriguchi H Tanaka Y Sasaki, J Antibiot (Tokyo) 1991 44 1 113 116 1848215
49. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. G Fenteany RF Standaert WS Lane S Choi EJ Corey SL Schreiber, Science 1995 268 5211 726 731 10.1126/science.7732382 7732382
50. Epoxomicin, a new antitumor agent of microbial origin. M Hanada K Sugawara K Kaneta S Toda Y Nishiyama K Tomita H Yamamoto M Konishi T Oki, J Antibiot (Tokyo) 1992 45 11 1746 1752 1468981
51. Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology. N Sin KB Kim M Elofsson L Meng H Auth BH Kwok CM Crews, Bioorg Med Chem Lett 1999 9 15 2283 2288 10.1016/S0960- 894X(99)00376-5 10465562
52. Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. B Ravikumar R Duden DC Rubinsztein, Hum Mol Genet 2002 11 9 1107 1117 10.1093/hmg/11.9.1107 11978769
53. Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation. S Waelter A Boeddrich R Lurz E Scherzinger G Lueder H Lehrach EE Wanker, Mol Biol Cell 2001 12 5 1393 1407 11359930
54. Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro. Y Chai SL Koppenhafer SJ Shoesmith MK Perez HL Paulson, Hum Mol Genet 1999 8 4 673 682 10.1093/hmg/8.4.673 10072437
55. Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice. CJ Cummings E Reinstein Y Sun B Antalffy Y Jiang A Ciechanover HT Orr AL Beaudet HY Zoghbi, Neuron 1999 24 4 879 892 10.1016/S0896-6273(00)81035-1 10624951
56. Identification of genes that modify ataxin-1-induced neurodegeneration. P Fernandez-Funez ML Nino-Rosales B de Gouyon WC She JM Luchak P Martinez E Turiegano J Benito M Capovilla PJ Skinner, Nature 2000 408 6808 101 106 10.1038/35040584 11081516
57. Aggregate formation inhibits proteasomal degradation of polyglutamine proteins. LG Verhoef K Lindsten MG Masucci NP Dantuma, Hum Mol Genet 2002 11 22 2689 2700 10.1093/hmg/11.22.2689 12374759
58. Trehalose reduces aggregate formation and delays pathology in a transgenic mouse model of oculopharyngeal muscular dystrophy. JE Davies S Sarkar DC Rubinsztein, Hum Mol Genet 2006 15 1 23 31 10.1093/hmg/ddi422 16311254
59. Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. I Sanchez C Mahlke J Yuan, Nature 2003 421 6921 373 379 10.1038/nature01301 12540902
60. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. L Mangiarini K Sathasivam M Seller B Cozens A Harper C Hetherington M Lawton Y Trottier H Lehrach SW Davies, Cell 1996 87 3 493 506 10.1016/S0092-8674(00)81369-0 8898202
61. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. A Yamamoto JJ Lucas R Hen, Cell 2000 101 1 57 66 10.1016/S0092-8674(00)80623-6 10778856
62. SCA7 knockin mice model human SCA7 and reveal gradual accumulation of mutant ataxin-7 in neurons and abnormalities in short-term plasticity. SY Yoo ME Pennesi EJ Weeber B Xu R Atkinson S Chen DL Armstrong SM Wu JD Sweatt HY Zoghbi, Neuron 2003 37 3 383 401 10.1016/S0896-6273(02)01190-X 12575948
63. Puromycin-sensitive aminopeptidase is the major peptidase responsible for digesting polyglutamine sequences released by proteasomes during protein degradation. NP Bhutani, EMBO J 2007 26 5 1385 1396 10.1038/sj.emboj.7601592 17318184
64. Global changes to the ubiquitin system in Huntington's disease. EJ Bennett, Nature 2007 448 7154 704 708 10.1038/nature06022 17687326